CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -203.9%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
380.17BKRW273.94M · vs all stocks (USD)
Revenue (TTM)
0.00KRWvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7630xvs all stocks
52-Week Change
-27.46%vs all stocks
Market Capitalization
380.17BKRW273.94M · vs all stocks (USD)
Enterprise Value
394.77BKRW284.46M · vs all stocks (USD)
Price to Book (MRQ)
15.00xvs Biotechnology peers
Enterprise to EBITDA
-12.47xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-23.50%vs Biotechnology peers
Return on Equity (TTM)
-203.85%vs Biotechnology peers
Revenue (TTM)
0.00KRWvs all stocks (USD)
Gross Profit (TTM)
-17.43MKRW-12.56K · vs all stocks (USD)
EBITDA (TTM)
-31.65BKRW-22.81M · vs all stocks (USD)
Net Income (TTM)
-48.20BKRW-34.73M · vs all stocks (USD)
Operating Cash Flow (TTM)
-31.98BKRW-23.05M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.48BKRW-6.11M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Operating Income
-36.29BKRW-26.15M · vs all stocks (USD)
Pre-tax Income
-46.31BKRWFY2025 · Dec 31, 2025Net Income
-46.31BKRWFY2025 · Dec 31, 2025EBIT
-41.76BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.47BKRWFY2025 · Dec 31, 2025Research & Development
31.25BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.04BKRWFY2025 · Dec 31, 2025Other Operating Expenses
204.89MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
457.72MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
4.54BKRWFY2025 · Dec 31, 2025EPS (Basic)
-3.23KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-3.23KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
14.33MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
14.33MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-46.31BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-42.20BKRWFY2025 · Dec 31, 2025Free Cash Flow
-42.50BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
10.16BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-46.31BKRWFY2025 · Dec 31, 2025Stock-based Compensation
953.87MKRWFY2025 · Dec 31, 2025Other Non-cash Items
4.09BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-41.02MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-895.30MKRWFY2025 · Dec 31, 2025Capital Expenditures
-300.68MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.90BKRWFY2025 · Dec 31, 2025Purchase of Investments
-55.49BKRWFY2025 · Dec 31, 2025Sale of Investments
48.29BKRWFY2025 · Dec 31, 2025Other Investing Activity
207.20MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.29BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
43.00BKRWFY2025 · Dec 31, 2025Other Financing Charges
56.84MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
45.34BKRWFY2025 · Dec 31, 2025Shares Outstanding
15.06MSharesUpdated Aug 20, 2026Float Shares
9.50MSharesUpdated Aug 20, 2026% Held by Insiders
37.07%vs all stocks
% Held by Institutions
7.81%vs all stocks
Total Cash (MRQ)
16.20BKRW11.67M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.10KKRWUpdated Aug 20, 2026Total Debt (MRQ)
48.19BKRW34.72M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.96xvs Biotechnology peers
Current Ratio (MRQ)
0.3610xvs Biotechnology peers
Book Value per Share (MRQ)
1.67KKRWUpdated Aug 20, 2026Total Assets
109.72BKRW79.06M · vs all stocks (USD)
Total Current Assets
32.34BKRWFY2025 · Dec 31, 2025Total Liabilities
104.70BKRWFY2025 · Dec 31, 2025Total Non-current Assets
77.38BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
7.68BKRWFY2025 · Dec 31, 2025Total Current Liabilities
97.01BKRWFY2025 · Dec 31, 2025Cash Equivalents
10.16BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
10.16BKRWFY2025 · Dec 31, 2025Other Short-term Investments
14.00BKRWFY2025 · Dec 31, 2025Inventory
1.68BKRWFY2025 · Dec 31, 2025Short-term Debt
55.32BKRWFY2025 · Dec 31, 2025Other Current Liabilities
890.00KRWFY2025 · Dec 31, 2025Long-term Debt
1.36BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-190.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
7.22BKRWFY2025 · Dec 31, 2025Retained Earnings
-245.32BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
5.03BKRW3.62M · vs all stocks (USD)
52-Week Low
20.65KKRWUpdated Aug 20, 202652-Week High
66.00KKRWUpdated Aug 20, 202652-Week Change
-27.46%vs all stocks
Beta
0.7630xvs all stocks
50-Day MA
27.16KKRWUpdated Aug 20, 2026200-Day MA
42.09KKRWUpdated Aug 20, 2026Avg 10-Day Volume
49.89KSharesUpdated Aug 20, 2026Avg 30-Day Volume
52.88KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-3.23KKRWUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -203.9%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.04Industry median: -0.22Industry P5: -1.66Peers compared: 261
Current ratio is 0.36×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.36Industry median: 5.64Industry P5: 1.06Peers compared: 261
Debt-to-equity is 1.96×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.96Industry median: 0.09Industry P95: 0.88Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alx Oncology Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Proteina Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMaking
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Shanghai Fudan Microelectronics Group Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline